A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
May 10, 2021
End Date
May 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
May 10, 2021
End Date
May 14, 2026